References
- Farquhar C, Marjoribanks J, Basser R, Hetrick SE, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005;(3):CD003139.
- Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679–87.
- Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients witn synchronous metastatic colorectal cancer. Ann Oncol 2013;24:2354–60.
- Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–9.
- Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent DJ, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational study (BRiTE). J Clin Oncol 2008;26:5326–34.
- Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) a randomised phase 3 trial. Lancet Oncol 2013;14:29–37.
- Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 2014;15:601–11.
- Nordlinger B, Poston GJ, Goldberg RM. Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J Clin Oncol Epub 2014 Nov 28.
- Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes H-G, Valdix AR, et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study. Acta Oncol Epub 2014 Oct 13.
- Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B. The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study. Acta Oncol Epub 2014 Oct 28.
- Saltz LB. Progress in cancer care: The hope, the hype and the gap between reality and perception. J Clin Oncol 2008;26:5020–1.
- Pusztai L, Hatzis C, Andre F. Reproducibility of research and preclinical validation: Problems and solutions. Nature Rev Clin Oncol 2013;10:720–4.